Digital Twin of Immunity: Russian Mathematical Model Aims to Accelerate Drug Development for Arthritis and Diabetes
核心洞察
Scientists from Sechenov University (搜索) and Russian Academy of Sciences built a mathematical model of B-cell immune response using 20 ordinary differential equations.
The model identifies two critical factors determining immune response strength: initial B-cell antigen contact and bone marrow microenvironment state.
The quantitative systems pharmacology (QSP) model enables virtual experiments to predict patient variability in drug response before clinical trials.
A team of Russian scientists has constructed a computational model that simulates the entire lifecycle of B-lymphocytes, offering a powerful new tool to predict immune response variability and accelerate drug development for autoimmune diseases. The work, a collaboration between Sechenov University (搜索), the Institute of Computational Mathematics of the Russian Academy of Sciences (搜索), and the company SimurgPharm (搜索), was published in the journal Frontiers in Immunology.
The model belongs to the class of quantitative systems pharmacology (QSP) and consists of a system of 20 ordinary differential equations. It describes the complete trajectory of B-lymphocytes — from their origin in the bone marrow, through migration into tissues, to their final transformation into antibody-producing plasma cells.
Two Critical Factors Identified
Through their modeling work, the researchers pinpointed two key determinants of immune response strength: the initial contact of a naive B-cell with an antigen, and the state of the bone marrow microenvironment. These factors help explain a persistent challenge in drug development — why the same therapeutic agent can produce a robust effect in some patients while showing almost no efficacy in others.
Kirill Peskov, head of the mathematical modeling center, told Izvestia that the model "helps to explain the variability of the immune response and take it into account already at the stage of planning clinical trials." By running virtual experiments based on the model's parameters, developers can simulate differential patient responses before enrolling human subjects.
Clinical Applications and Future Expansion
The platform is designed to be modular and extensible. According to the developers, it can be supplemented with new diseases and drug mechanisms of action. The anticipated therapeutic areas for application include rheumatoid arthritis (搜索), type 1 diabetes mellitus (搜索), and multiple sclerosis (搜索) — all conditions in which B-cell-mediated immune responses play a central pathological role.
By integrating this digital twin approach into early-stage drug development, the researchers aim to reduce both the time and financial cost associated with bringing new therapies to market for these autoimmune indications.